|
Post by patten1962 on Nov 12, 2016 9:20:18 GMT -5
Just talking here. Do you remember the conference call about a year ago, Hakan was on it, when gs and jpm were still covering MNKD, In the question and answer period an individual from china said he wanted to invest in MNKD and had resources. the exchange a bit difficult in that moment. Sanofi still involved? Do you remember? Any connection? I remember the guy at the last annual shareholder meeting ..... He wanted controlling intrest in the company. Matt and the board did not even consider it I was told at the meeting.
|
|
|
Post by patten1962 on Nov 12, 2016 9:23:13 GMT -5
I remember the guy at the last annual shareholder meeting ..... That guy was about 10 feet from me at the ASM. He is not associated with Amphastar. Amphastar has been after Mannkind for some time. MNKD may be better served doing a deal with San Meditech or others and just giving whoever a marketing and distribution agreement. The good news with Amphastar was MNKD was not so desperate where they needed to do the deal when it seemed like Amphastar had them over a barrel. Given that and the fact that Mike is very upbeat and put his own money in and Matt seems to have ZERO concerns about money, gives me great hope. I am still waiting on the $200M PO from Al's tiny country, hope springs eternal. I wad at the meeting. Did I meet you? Hard to face with pro board name?
|
|
|
Post by buyitonsale on Nov 12, 2016 23:52:10 GMT -5
When someone offers any sum of money for controlling interest to Mannkind, it only means one thing... management gets fired the next day and the same controlling interest is sold to BP for double the price. The end.
|
|
|
Post by mango on Nov 13, 2016 0:12:04 GMT -5
When someone offers any sum of money for controlling interest to Mannkind, it only means one thing... management gets fired the next day and the same controlling interest is sold to BP for double the price. The end. Smart move by MannKind. If you don't like the ship, jump off.
|
|
|
Post by Chris-C on Nov 13, 2016 14:36:50 GMT -5
Although the record seems to have been set straight with respect to Mr. Orloski and the Chinese investors (the audio was difficult in that shareholder meeting video for comments from the audience), I think all of us agree that any sizeable investments to extend the cash runway would be very beneficial and would go a long way toward increasing the share price out of "delisting" territory before within the six month window. It seems realistic to accept that the success of Afrezza will require time and smart marketing and excellent patient support. Doing these two things right requires patience and time. With the cash burn rate as it is, a longer window (i.e. cash reserves) allows for more sales visits, more scripts, and more success stories. It also increases the cost of shorting the stock and the fears of a short squeeze. Given the share price, at some point the cost benefit ratio leads to covering, especially when good things start piling up. I remember Akamai at .65 in 2002 and skies were dark. It now trades at $65.00. As we know, the only certain thing is that change will occur. The last week has shown us that with exclamation points.
|
|
|
Post by kc on Nov 13, 2016 17:37:55 GMT -5
I remember the guy at the last annual shareholder meeting ..... He wanted controlling intrest in the company. Matt and the board did not even consider it I was told at the meeting. His approach was not very professional. That is not the way you try to buy into a public company. My eyes very amateurish
|
|
|
Post by buyitonsale on Nov 14, 2016 1:50:49 GMT -5
When someone offers any sum of money for controlling interest to Mannkind, it only means one thing... management gets fired the next day and the same controlling interest is sold to BP for double the price. The end. Smart move by MannKind. If you don't like the ship, jump off. 1. What do you think my post meant? 2. Childish
|
|
|
Post by cgiscgis on Nov 14, 2016 5:47:42 GMT -5
Amphstar website has been down since MannKind mentioned them!
|
|
|
Post by falconquest on Nov 14, 2016 6:25:04 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 14, 2016 7:18:40 GMT -5
Amphstar website has been down since MannKind mentioned them! Looks like you are reading too much into Kevin posts and have his virus
|
|
|
Post by mango on Nov 14, 2016 9:54:33 GMT -5
Amphastar website works for me too.
RLS website works fine too, and the trees are back up
|
|
|
Post by kc on Nov 14, 2016 21:21:59 GMT -5
Amphstar website has been down since MannKind mentioned them! Looks like you are reading too much into Kevin posts and have his virus Seems like Kevin disappeared from StockTwits.
|
|
|
Post by lakers on Nov 26, 2016 2:33:50 GMT -5
Mnkd copies a page from Dance Biopharm's China Licensee, Harmony Biopharm, Enters into New Joint Venture with Tonghua Dongbao Pharmaceutical, a Leading China Insulin Producer www.prnewswire.com/news-releases/dance-biopharms-china-licensee-harmony-biopharm-enters-into-new-joint-venture-with-tonghua-dongbao-pharmaceutical-a-leading-china-insulin-producer-300264087.htmlSAN FRANCISCO, May 6, 2016 /PRNewswire/ -- Dance Biopharm Inc. ("Dance"), a privately-held biotechnology company focused on the development of Dance 501, an inhaled insulin product to treat diabetes, is pleased to announce that Harmony Biopharm Limited, Dance's licensee for Dance 501 in Asia, has recently formed a joint venture with Tonghua Dongbao Pharmaceutical Co. and Shanghai Dongbao Biological Pharmaceutical Co. (collectively, "Dongbao"). The joint venture will focus on obtaining regulatory approval in China and, if approval is obtained, preparing for commercialization of Dance 501. According to the International Diabetes Federation, there are more than 110 million diabetes patients in China, the highest of any country in the world. Dongbao, Dance's global insulin supplier, has been making and selling injectable insulin for more than 25 years. Its high-capacity insulin factory in Northern China has been inspected and qualified by the European Medicines Agency. Through the new joint venture, Dongbao has committed to shared responsibility with Harmony Biopharm to develop and commercialize Dance 501 in Greater China. The initial capitalization of the joint venture is U.S. $11 million. About Dongbao Dongbao Enterprise Group is a China conglomerate with more than 20 subsidiaries focused on the production and manufacture of recombinant therapeutics, especially human insulin, and is a leading manufacturer of insulin in Asia. Tonghua Dongbao Pharmaceutical, one of the 20 subsidiaries, is a public company listed on the Shanghai Stock Exchange. Shanghai Dongbao Biological Pharmaceutical Co, also a subsidiary of Dongbao Enterprise Group assists Tonghua Dongbao Pharmaceutical Co. in the registration and operation of its overseas insulin products market. About Harmony Biopharm Ltd Harmony Biopharm, a private Hong Kong company, has licensed Dance Biopharm's technology for development and commercialization in the Asia Pacific market. About Dance 501, an Inhaled Insulin Product Dance 501 consists of a high purity liquid formulation of recombinant human insulin stored in a dispenser for administration with a small handheld electronic inhaler. The electronic inhaler utilizes a patented vibrating mesh technology, designed to produce consistently sized particles of liquid insulin in the form of a smooth mist, allowing the efficient and consistent delivery of insulin into the lungs in a few breaths. Dance 501 has not yet been approved by any regulatory authority. About Dance Biopharm Inc. Dance Biopharm is a privately-held company based in the San Francisco Bay Area focused on the clinical development of inhaled insulin products to treat diabetes patients worldwide. The company began operations in 2010, founded by Dr. John Patton, who has over 25 years of experience developing inhaled insulin and other inhaled therapies.
|
|
|
Post by cjm18 on Nov 26, 2016 12:21:22 GMT -5
"Dance 501 has not yet been approved by any regulatory authority"
Couldn't find one any article about the insulin since this one.
|
|